Clik here to view.
ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted...
MUNICH & GARCHING, Germany & HONG KONG ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Grand Pharmaceutical Group Limited (GP) a diversified...
View ArticleClik here to view.
Accutar Biotechnology宣布FDA批准AC0176用于治疗前列腺癌的1期试验的IND申请
纽约布鲁克林 (美国商业资讯)–专注于利用人工智能(AI)赋能药物发现的生物技术公司Accutar Biotechnology, Inc.今天宣布，美国食品药品管理局(FDA)已批准该公司在研新药AC0176用于治疗转移性去势难治性前列腺癌(mCRPC)患者的试验用新药申请(IND)。AC0176是一种口服生物可利用(orally...
View ArticleClik here to view.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for...
KENILWORTH, N.J. & TOKYO Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has...
View ArticleClik here to view.
Valemetostat New Drug Application Submitted in Japan for Treatment of...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour...
View ArticleClik here to view.
RIBOMIC Announces Preliminary Topline Data From Phase 2 Trials of RBM-007 for...
TOKYO RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the topline data from the Phase 2 TOFU study of RBM-007 in patients...
View ArticleClik here to view.
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics...
View ArticleClik here to view.
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics...
View ArticleClik here to view.
Babson Graduate Pooja Ika Launches eternalHealth, the First New Medicare...
BOSTON eternalHealth, the first new health plan to be approved in Massachusetts since 2013, has officially announced its launch of the company, delivering high-quality and affordable Medicare...
View ArticleClik here to view.
GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune...
YONGIN, South Korea & MUMBAI, India GC Cell (KOSDAQ:144510) and Rivaara Immune Private Limited today announced that they have entered into an exclusive licensing agreement, pursuant to which...
View ArticleClik here to view.
Full-Life Technologies Announces Senior Executive Team Appointments
BOSTON & BRUSSELS & SHANGHAI Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team. Joining the company are Ravi Chari, Ph.D. Chief Scientific Officer;...
View ArticleClik here to view.
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark...
BOSTON Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper...
View ArticleClik here to view.
Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and...
MENLO PARK, Calif. Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today...
View ArticleClik here to view.
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P....
View ArticleClik here to view.
Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of...
TOKYO Cellusion Inc., a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal...
View ArticleClik here to view.
イクスーダ・セラピューティクス、レゴケム・バイオサイエンシズからのHer2抗体薬物複合体プログラムのライセンス契約により、臨床パイプラインを強化
英ニューカッスル （ビジネスワイヤ） — 治療指数を高めた新世代の抗体薬物複合体（ADC）の開発を手掛けるイクスーダ・セラピューティクス（イクスーダ）は本日、専有的な創薬技術を活用した次世代の新規治療薬の開発に傾注する韓国のバイオ製薬企業レゴケム・バイオサイエンシズ（LCB）とライセンス／商業化契約を結び、当社の差別化ADCパイプラインをさらに拡大すると発表しました。...
View ArticleClik here to view.
Clik here to view.
Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线
英国纽卡斯尔 (美国商业资讯)–开发新一代高治疗指数抗体药物偶联物(ADC)的公司Iksuda Therapeutics (Iksuda)今天宣布，将通过与韩国生物制药公司LegoChem Biosciences (LCB)所签的许可和商业化协议，进一步扩大公司差异化的ADC产品线。LCB专注于运用其专有药物发现技术开发下一代新型治疗药物。 该协议向Iksuda提供LCB的Her2...
View ArticleClik here to view.
武田薬品、Adaptate Biotherapeutics社を買収し、固形がんを標的とする新規ガンマデルタ（γδ）T細胞エンゲージャー療法の開発を推進
日本・大阪および英国ロンドン （ビジネスワイヤ） — 武田薬品工業株式会社 (TSE:4502/NYSE:TAK)（以下、「武田薬品」）は本日、可変デルタ1 （Vδ1）ガンマデルタ（γδ）T細胞を修飾し抗体ベースの治療薬の開発を進める英国に本拠を置く企業であるAdaptate Biotherapeutics...
View ArticleClik here to view.
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ)...
OSAKA, Japan & LONDON Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK...
View ArticleClik here to view.